Search Results

You are looking at 51 - 60 of 401 items for :

  • "adjuvant chemotherapy" x
Clear All
Full access

Gary H. Lyman

body-mass index . Lancet 2005 ; 366 : 1108 – 1110 . 27 Hershman DL Wang X McBride R . Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women . Breast Cancer Res Treat 2006 ; 99 : 313 – 321

Full access

Clayton A. Smith and Lisa A. Kachnic

significant benefit to overall survival (OS). 4 Adjuvant chemotherapy both reduced the rate of distant metastases and improved disease-free survival (DFS). 5 , 6 This review focuses on the current treatment paradigms for LARC and highlights clinical trials

Full access

Carmen P. Escalante, Ellen Manzullo and Rosalie Valdres

and correlates of fatigue after adjuvant chemotherapy for breast cancer . J Clin Oncol 1998 ; 16 : 1689 – 1696 . 9 Mendoza TR Wang XS Cleeland CS The rapid assessment of fatigue in cancer patients . Cancer 1999 ; 85 : 1186

Full access

Ali Raza Khaki, V.K. Gadi and Vinay Prasad

Multiple predictive assays have been implemented into clinical practice to help determe which women with early-stage hormone-sensitive breast cancer may benefit from adjuvant chemotherapy and which may not. These assays were originally developed as

Full access

Shaneli A. Fernando and Stephen B. Edge

adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic

Full access

Bach Peter B. MD, MAPP 03 2008 6 6 3 3 271 271 275 275 0060271 10.6004/jnccn.2008.0022 Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only? Morgensztern Daniel MD Govindan Ramaswamy MD 03 2008 6 6 3 3 277 277 284

Full access

Rebecca P. Petersen and David H. Harpole Jr.

results . Clin Cancer Res 2005 ; 11 [ suppl 13 ]: 4984 – 4987 . 16. Kato H Ichinose Y Ohta M . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung . N Engl J Med 2004 ; 350 : 1713 – 1721

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Full access

Scott M. Schuetze

sarcoma: eight-year experience with adjuvant chemotherapy . J Cancer Res Clin Oncol 1983 ; 106 ( suppl ): 55 – 67 . 16. Sutow WW Sullivan MP Fernbach DJ . Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory and Deborah A. Freedman-Cass

rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on